Cytosorbents Corporation
Last updated September 27, 2026
Organization details
- Legal name
- Cytosorbents Corporation
- Former names
- MedaSorb Technologies CORP Gilder Enterprises Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 3841 — Surgical & Medical Instruments & Apparatus
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Princeton
- Headquarters state / province
- New Jersey
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CTSO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001175151
- EIN
- 98-0373793
Board of directors
-
Al Kraus · DirectorSince 2023
-
Alan D. Sobel · DirectorSince 2023
-
Edward Raymond Jones · DirectorSince 2023
-
Jiny Kim · DirectorSince 2023
-
Michael G. Bator · DirectorSince 2023
-
Phillip P. Chan · Director · Chief Executive OfficerSince 2023
Chief executives
Phillip P. Chan
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of August 13, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
87.2%
-
87.2%
-
87.8%
-
87.9%
-
91.4%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $269,332
- 10 purchases by 4 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 15, 2026 | Phillip P. Chan Director, Officer (Chief Executive Officer) | Open-market purchase | +3,774 | $6.00 | $22,644 |
| Sep 15, 2026 | Alan D. Sobel Director | Open-market purchase | +1,900 | $6.12 | $11,628 |
| Sep 15, 2026 | Alan D. Sobel Director | Open-market purchase | +500 | $6.05 | $3,025 |
| Sep 15, 2026 | Alan D. Sobel Director | Open-market purchase | +100 | $6.01 | $601 |
| Sep 14, 2026 | Capponi Vincent Officer (President and COO) | Open-market purchase | +1,800 | $6.07 | $10,926 |
| Sep 14, 2026 | Capponi Vincent Officer (President and COO) | Open-market purchase | +273 | $5.90 | $1,611 |
| Sep 4, 2026 | Phillip P. Chan Director, Officer (Chief Executive Officer) | Open-market purchase | +200,000 | $0.35 | $70,000 |
| Jun 15, 2026 | MARIANI PETER J Officer (Chief Financial Officer) | Open-market purchase | +100,000 | $0.44 | $44,000 |
| Jun 15, 2026 | Phillip P. Chan Director, Officer (Chief Executive Officer) | Open-market purchase | +10,333 | $0.43 | $4,443 |
| Jun 12, 2026 | Phillip P. Chan Director, Officer (Chief Executive Officer) | Open-market purchase | +251,136 | $0.40 | $100,454 |
| Nov 18, 2025 | Phillip P. Chan Director, Officer (Chief Executive Officer) | Grant or award | +100,000 | $0.64 | $64,000 |
| Aug 8, 2025 | Phillip P. Chan Director, Officer (Chief Executive Officer) | Grant or award | +105,600 | — | — |
| Aug 8, 2025 | MARIANI PETER J Officer (Chief Financial Officer) | Grant or award | +71,500 | — | — |
| Aug 8, 2025 | Capponi Vincent Officer (President and COO) | Grant or award | +89,100 | — | — |
| Aug 8, 2025 | Deliargyris Efthymios Officer (Chief Medical Officer) | Grant or award | +70,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.